COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 163

Sponsor: University Hospital, Montpellier

Location: Centre hopsitalier universitaire de Montpellier Montpellier Occitanie

Summary

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

Eligibility Criteria

Inclusion Criteria: * Patients with rheumatoid arthritis or spondyloarthritis * With positive serology for SARS-CoV-2 infection less than 3 months old at the time of inclusion * Under biotherapy, or conventional synthetic Disease-modifying antirheumatic drugs (csDMARD) or Nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids for at least one month during the year 2020 * Agreeement to participate two years in the study Exclusion Criteria: * Pregnant or breastfeeding woman * Refusal to participate in the study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04530682). StuddyBuddy aggregates publicly available trial information.